<DOC>
	<DOCNO>NCT01744821</DOCNO>
	<brief_summary>The purpose research study Vitamin D3 replacement patient high risk develop ovarian , fallopian tube , peritoneal cancer , see Vitamin D3 replacement may able prevent cancer . This study do United States ovarian cancer lead cause death among woman gynecologic cancer . Women BRCA mutation , personal history breast cancer , family history breast ovarian cancer high risk develop ovarian , fallopian , primary peritoneal cancer . Novel treatment surgery decrease risk develop ovarian , fallopian tube , primary peritoneal cancer important . Vitamin D show reduce risk develop bladder , breast , colon , endometrial , esophageal , gallbladder , gastric , lung , pancreatic , prostate , rectal , renal , vulvar Hodgkin non-Hodgkin lymphoma , may play role prevention ovarian cancer .</brief_summary>
	<brief_title>Vitamin D Women Increased Risk Developing Ovarian , Fallopian , Primary Peritoneal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>Patients must undergo prophylactic therapeutic oophorectomy Patients must consider high risk develop ovarian , fallopian primary peritoneal cancer , accord 1 follow characteristic : Patients BRCA mutation include variant uncertain significance Patients Lynch syndrome Patients family history place high risk develop ovarian cancer Patients personal history breast cancer Patients currently take Vitamin D prior registration eligible serum Vitamin D level &lt; 60ng/ml . We believe patient low replacement dos Vitamin D3 begin order prevent toxicity Vitamin D3 level check start trial . Patients must woman age 18 old Patients childbearing potential sexually active must use contraception study . Patients must sign witness informed consent authorization permit release personal health information prior registration study . Patients unable take Vitamin D3 supplementation NOT eligible Patients unwilling unable undergo oophorectomy NOT eligible Patients suspicious abnormal finding preoperative physical exam , laboratory result , image study within 4 week treatment start NOT eligible Patients GFR &lt; 59 within 4 week treatment start NOT eligible Patients NOT eligible exhibit contraindication within 4 week treatment start 25 ( OH ) D supplement include : Hypercalcemia ( &gt; 11.5mg/dL ) Hypervitaminosis D Malabsorption syndrome Active gallbladder disease Active hepatic disease Hypoparathyroidism Leukemia Nephrolithiasis Renal failure sarcoidosis Renal disease ( eGFR &lt; 59 ml/min/1.73m2 ) Patients currently receive digoxin NOT eligible Patients pregnant breastfeed NOT eligible . Patients must negative urine pregnancy test baseline ( within 4 week treatment start ) confirm eligibility</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>High Risk</keyword>
</DOC>